SENTI BIOSCIENCES INC has a total of 35 patent applications. It decreased the IP activity by 14.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and China. Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are INTROGENE BV, EMENDOBIO INC and HEMA QUEBEC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 11 | |
#2 | United States | 5 | |
#3 | China | 4 | |
#4 | EPO (European Patent Office) | 4 | |
#5 | Australia | 3 | |
#6 | Canada | 3 | |
#7 | Republic of Korea | 3 | |
#8 | Israel | 1 | |
#9 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides | |
#5 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Lu Timothy Kuan-Ta | 25 |
#2 | Wong Remus | 14 |
#3 | Gordley Russell Morrison | 14 |
#4 | Lee Philip Janmin | 13 |
#5 | Garrison Brian Scott | 12 |
#6 | Lin Jack Tzu-Chiao | 11 |
#7 | Gonzalez-Junca Alba | 10 |
#8 | Wang Don-Hong | 7 |
#9 | Gordley Russell | 6 |
#10 | Frimannsson Daniel | 5 |
Publication | Filing date | Title |
---|---|---|
WO2021041920A1 | Combinatorial cancer immunotherapy | |
WO2021035093A1 | Chimeric inhibitory receptor | |
WO2020223445A1 | Chimeric receptors and methods of use thereof | |
WO2020154635A1 | Fusion constructs for controlling protein function | |
US2020171093A1 | Combinatorial cancer immunotherapy | |
WO2019222642A1 | Engineered immune cells and methods of use | |
WO2019118518A2 | Inducible cell receptors for cell-based therapeutics | |
US2020206271A1 | Combinatorial cancer immunotherapy | |
US2020085876A1 | Immunomodulating cell circuits | |
CA3031670A1 | Spatiotemporal regulators |